Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03689595 · ClinicalTrials.gov registry record
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
A clinical trial of Multiple Myeloma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 30,000
- Enrollment target
- 1
- Study location
NCT03689595: Recruiting study of Multiple Myeloma, sponsored by Dana-Farber Cancer Institute.
NCT03689595 is a study of Multiple Myeloma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 30,000 participants, above the 478-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (6176% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03689595, a study of Multiple Myeloma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 30,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Conditions Studied
Interventions
- OTHER Sample of Blood
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,000 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2033-10-31 |
What NCT03689595 shows while recruiting
NCT03689595 is an observational study that tracks outcomes without assigning an intervention. Its 30,000 participants enrollment target places it among the larger protocols in the corpus, above the 478-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (6176% higher).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Sample of Blood is the first listed.
NCT03689595 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03689595 about?
NCT03689595 is a clinical study titled "Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)". The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progres...
What is the current status of trial NCT03689595?
This trial is currently recruiting. The enrollment target is 30,000 participants. The study started on 2018-10-31. Estimated completion is 2033-10-31.
What conditions does trial NCT03689595 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03689595?
The interventions under investigation include: Sample of Blood (OTHER).
Who is sponsoring clinical trial NCT03689595?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03689595 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03689595's enrollment target sits among peer trials
30,000 2nd of 438 the highest of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03053193 · 30,000 participants
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- NCT04834869 · 30,000 participants
COVID-19 Vaccines Safety Tracking (CoVaST)
- NCT05484804 · 30,000 participants · NA
Accountability for Care Through Undoing Racism & Equity for Moms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI